Journal of Blood Medicine
Comparative Outcomes of Generic and Branded Dasatinib in Chronic-Phase Chronic Myeloid Leukemia: A Single-Center Within-Patient Analysis
By Anas Mohamed Babiker, Elrazi Ali, Alaa Abdullah Ali Rahhal and 4 others.
Abstract
Background
Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukaemia (CML) from a fatal malignancy into a manageable chronic condition. Second-generation TKIs, including dasatinib, achieve faster, deeper molecular responses and overcome imatinib resistance or intolerance. However, high acquisition costs limit access, particularly in resource-constrained settings. The FDA approval of generic dasatinib in September 2024 represents a landmark step towards affordability.